2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162208
    HSD17B13-IN-55 2770247-58-8 98%
    HSD17B13-IN-55 (Compound 167) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-55 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-55
  • HY-162209
    HSD17B13-IN-63 2770247-51-1 98%
    HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-63
  • HY-162210
    HSD17B13-IN-65 2770247-59-9 98%
    HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-65
  • HY-162211
    HSD17B13-IN-84 2770247-73-7 98%
    HSD17B13-IN-84 (182) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-84
  • HY-162212
    HSD17B13-IN-85 2770247-76-0 98%
    HSD17B13-IN-85 (186) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-85
  • HY-162213
    HSD17B13-IN-86 2770247-78-2 98%
    HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-86
  • HY-162214
    HSD17B13-IN-90 2848620-81-3 98%
    HSD17B13-IN-90 (4) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-90
  • HY-162215
    HSD17B13-IN-88 2770247-93-1 98%
    HSD17B13-IN-88 (Compound 200) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor with an IC50 of ≤0.1 μM for Estradiol.
    HSD17B13-IN-88
  • HY-162216
    HSD17B13-IN-89 2770247-94-2 98%
    HSD17B13-IN-89 (206) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-89
  • HY-162217
    HSD17B13-IN-91 2848620-83-5 98%
    HSD17B13-IN-91 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-91 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-91
  • HY-162219
    HSD17B13-IN-93 2848620-87-9 98%
    HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-93
  • HY-162220
    HSD17B13-IN-94 2848620-90-4 98%
    HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI).
    HSD17B13-IN-94
  • HY-162221
    HSD17B13-IN-95 2849338-41-4 98%
    HSD17B13-IN-95 (1) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease.
    HSD17B13-IN-95
  • HY-162222
    HSD17B13-IN-96 2849338-43-6 98%
    HSD17B13-IN-96 (3) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease.
    HSD17B13-IN-96
  • HY-162223
    HSD17B13-IN-97 2849338-44-7 98%
    HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC50 value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI).
    HSD17B13-IN-97
  • HY-162224
    HSD17B13-IN-98 2849338-45-8 98%
    HSD17B13-IN-98 (5) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease.
    HSD17B13-IN-98
  • HY-162225
    HSD17B13-IN-99 2849338-46-9 98%
    HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-99
  • HY-162262
    α-Glucosidase-IN-48 98%
    α-Glucosidase-IN-48 (compound 9) is a potent inhibitor of α-Glucosidase, with IC50 of 1.30 μM.
    α-Glucosidase-IN-48
  • HY-162278
    HSD17B13-IN-101 98%
    HSD17B13-IN-101 is a selective inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for Estradiol is <0.1 μM. HSD17B13-IN-101 can be used in the study of nonalcoholic fatty liver disease (NAFLD) (WO2023146897A1; compound 94).
    HSD17B13-IN-101
  • HY-162298
    γ-Linolenoyl monoethanolamide 150314-37-7 98%
    γ-Linolenoyl monoethanolamide, a kind of fatty N-acyl ethanolamine, is an endocannabinoid.
    γ-Linolenoyl monoethanolamide
Cat. No. Product Name / Synonyms Application Reactivity